

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI154895

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
BIOSPLICE THERAPEUTICS, INC.	03/01/2024
RECEIVING PARTY DATA	
Company Name:	VICKERS VENTURE FUND VI PTE. LTD.
Street Address:	1 HARBOURFRONT AVENUE, #16-06
Internal Address:	KEPPEL BAY TOWER
City:	SINGAPORE
State/Country:	SINGAPORE
Postal Code:	098632
Company Name:	VICKERS VENTURE FUND VI (PLAN) PTE. LTD.
Street Address:	1 HARBOURFRONT AVENUE, #16-06
Internal Address:	KEPPEL BAY TOWER
City:	SINGAPORE
State/Country:	SINGAPORE
Postal Code:	098632
Company Name:	VICKERS-SPLICE CO-INVESTMENT LLC
Street Address:	WILLOW HOUSE, CRICKET SQUARE
Internal Address:	PO BOX 709
City:	GRAND CAYMAN
State/Country:	CAYMAN ISLANDS
Postal Code:	KY1-1107
Company Name:	MED-PATHWAYS II LIMITED
Street Address:	VISTRA CORPORATE SERVICES CENTRE WICKHAMS CAY II
Internal Address:	ROAD TOWN
City:	TORTOLA
State/Country:	VIRGIN ISLANDS, BRITISH
Postal Code:	BRITISH VG 1110
PROPERTY NUMBERS Total: 10	
Property Type	Number
Application Number:	17873818

Property Type	Number
Application Number:	17964423
Application Number:	17964470
Application Number:	17964489
Application Number:	17990133
Application Number:	18315047
Application Number:	18340543
Application Number:	63614120
PCT Number:	US2326100
PCT Number:	US2423387

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 5104992971

Email: luyue@pillarlegalpc.cn

Correspondent Name: Ms. Yue Lu

Address Line 1: 1990 N. California Blvd.

Address Line 4: Walnut Creek, CALIFORNIA 94596

NAME OF SUBMITTER:	Yue Lu
SIGNATURE:	Yue Lu
DATE SIGNED:	05/10/2024
	This document serves as an Oath/Declaration (37 CFR 1.63).

Total Attachments: 87

source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page1.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page2.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page3.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page4.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page5.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page6.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page7.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page8.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page9.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page10.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page11.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page12.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page13.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page14.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page15.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page16.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page17.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page18.tif

[illegible]

source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page67.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page68.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page69.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page70.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page71.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page72.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page73.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page74.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page75.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page76.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page77.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page78.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page79.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page80.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page81.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page82.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page83.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page84.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page85.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page86.tif
source=Exhibit C - IP Security Agreement (Final, 2024-3-1 with updated list)#page87.tif

EXHIBIT C
AMENDED AND RESTATED
INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Amended and Restated Intellectual Property Security Agreement (“Amended IP Security Agreement”), dated as of March 1, 2024, is made by and between Biosplice Therapeutics, Inc., a Delaware corporation (the “Grantor”), and Vickers Venture Fund VI Pte. Ltd., Vickers Venture Fund VI (Plan) Pte. Ltd., Vickers-Splice Co-Investment LLC and Med-Pathways II Limited as the lead noteholder (collectively, the “Lead Noteholder”) for the benefit of each of the Purchasers (as defined in the Purchase Agreement (as defined below)), now or from time to time hereafter party to that certain Secured Convertible Promissory Note Purchase Agreement dated as of September 12, 2022 (as amended from time to time, the “Purchase Agreement”). Capitalized terms used but not defined herein shall have the meanings ascribed thereto in the Security Agreement (as defined below).

RECITALS

WHEREAS, Under the terms of that certain Security Agreement, dated as of September 12, 2022, by and between the Grantor and Lead Noteholder (as amended from time to time, the “Security Agreement”), the Grantor has agreed to execute and deliver the IP Security Agreement dated as of September 12, 2022 for recording with governmental authorities, including the United States Patent and Trademark Office and the United States Copyright Office (the “Initial IP Security Agreement”);

WHEREAS, the Grantor and Lead Noteholder hereby wish to amend the Initial IP Security Agreement to, among other things, include the newly updated schedule of Patents (as defined below) and Trademarks (as defined below) for recording with governmental authorities, including the United States Patent and Trademark Office.

AGREEMENT

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1. **Grant of Security.** The Grantor hereby grants, pledges and assigns to the Lead Noteholder for the ratable benefit of the Secured Parties a continuing first priority Lien and security interest in and to all of the right, title, and interest of the Grantor in, to, and under the following (the “IP Collateral”):

(a) the patents and patent applications set forth in Schedule 1 hereto and all reissues, divisionals, continuations, renewals, extensions continuations-in-part and amendments thereto (the “Patents”);

(b) the trademark, trade name, trade dress, and domain name registrations and applications set forth in Schedule 2 hereto, together with the goodwill connected with the use thereof and symbolized thereby, and all extensions and renewals thereof (the “Trademarks”), excluding only United States intent-to-use trademark applications to the extent that, and solely during the period in which, the grant, attachment, or enforcement of a security interest therein would, under applicable federal law, impair the registrability of

such applications or the validity or enforceability of registrations issuing from such applications;

(c) the copyright registrations, applications, and copyright registrations and applications exclusively licensed to the Grantor set forth in Schedule 3 hereto, and all extensions and renewals thereof (the "Copyrights");

(d) all rights of any kind whatsoever of the Grantor corresponding to any of the foregoing throughout the world;

(e) any and all Proceeds now or hereafter due or payable with respect to any and all of the foregoing; and

(f) rights to sue for past, present or future infringements and misappropriations.

2. Recordation. The Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks, the Register of Copyrights, and any other government officials to file, record and/or register this Amended IP Security Agreement upon request by the Lead Noteholder.

3. Transaction Agreements. This Amended IP Security Agreement has been entered into pursuant to and in conjunction with the Security Agreement, which is hereby incorporated by reference. The provisions of the Security Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of the Lead Noteholder with respect to the IP Collateral are as provided by the Security Agreement, and related documents, and nothing in this Amended IP Security Agreement shall be deemed to limit such rights and remedies.

4. Counterparts; Facsimile. This Amended IP Security Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including .pdf or any electronic signature complying with the U.S. federal E-SIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

5. Successors and Assigns. This Amended IP Security Agreement will be binding on and shall inure to the benefit of the parties hereto and their respective successors and assigns.

6. Jurisdiction and Venue. This Amended IP Security Agreement is entered into in express reliance on Section 2708 of Title 6 of the Delaware Code. The parties hereto agree that the appropriate, exclusive and convenient forum for any disputes between any of the parties hereto arising out of or related to this Amended IP Security Agreement or the transactions contemplated hereby shall be in the Court of Chancery in Wilmington, Delaware (or, if such court lacks subject matter jurisdiction, then the federal district court in Wilmington, Delaware or, if such court lacks subject matter jurisdiction, then the Superior Court in Wilmington, Delaware). Each party hereto hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction of such courts for any Action, suit or proceeding arising out of or relating to this Amended IP Security Agreement or the transactions contemplated hereby (and agrees not to commence any Action, suit


or proceeding relating thereto except in such courts, and further agrees that service of any process, summons, notice or document by U.S. registered mail to the address set forth on Exhibit J of the Purchase Agreement applicable, shall be effective service of process for any Action, suit or proceeding brought in any such court). Each party hereto hereby irrevocably and unconditionally waives any objection which it may now or hereafter have to the laying of venue of any Action, suit or proceeding arising out of this Amended IP Security Agreement or the transactions contemplated hereby in such courts, and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such Action, suit or proceeding brought in any such court has been brought in an inconvenient forum.

[Signature Page Follows]

IN WITNESS WHEREOF, each party hereto has caused this Amended IP Security Agreement to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

GRANTOR:


BIOSPLICE THERAPEUTICS, INC.

By: 
Name: Cevdet Samikoglu
Title: Chief Executive Officer


IN WITNESS WHEREOF, each party hereto has caused this Amended IP Security Agreement to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

LEAD NOTEHOLDER:


**VICKERS VENTURE FUND VI PTE.
LTD.**

By: 
Name: Dr. Finian Tan
Title: Director

**VICKERS VENTURE FUND VI (PLAN)
PTE. LTD.**

By: 
Name: Dr. Finian Tan
Title: Director


**VICKERS-SPLICE CO-INVESTMENT
LLC**

By: 
Name: Dr. Finian Tan
Title: Director

IN WITNESS WHEREOF, each party hereto has caused this Amended IP Security Agreement to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

LEAD NOTEHOLDER:

MED-PATHWAYS II LIMITED

By:  _____
Name: Raymond Kong
Title: Director

SCHEDULES

SCHEDULE 1

PATENTS AND PATENT APPLICATIONS

PATENT

REEL: 067382 FRAME: 0011

Title	Appln	Publ. No.	Country
METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE WNT SIGNALING IN CANCER CELLS	61/051,322		UNITED STATES
METHODS FOR IDENTIFYING COMPOUNDS THAT AFFECT EXPRESSION OF CANCER-RELATED PROTEIN ISOFORMS	61/051,324		UNITED STATES
METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE WNT SIGNALING IN CANCER CELLS	61/083,870		UNITED STATES
METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE WNT SIGNALING IN CANCER CELLS	200980116859.6	CN102027133A	CHINA
METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE WNT SIGNALING IN CANCER CELLS	09743616.6	2283160	EUROPEAN PATENT CONVENTION
METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE WNT SIGNALING IN CANCER CELLS	PCT/US2009/043051	WO2009/137630	WIPO
METHODS FOR IDENTIFYING COMPOUNDS THAT AFFECT EXPRESSION OF CANCER-RELATED PROTEIN ISOFORMS	PCT/US2009/043052	W/2009/137631	WIPO
METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE WNT SIGNALING IN CANCER CELLS	12/437,318	US-2010-0068708-A1	UNITED STATES
METHODS FOR IDENTIFYING COMPOUNDS THAT AFFECT EXPRESSION OF CANCER-RELATED PROTEIN ISOFORMS	12/437,327	US-2009-0286246-A1	UNITED STATES
Wnt INHIBITORS AND METHODS OF USE	61/232,603		UNITED STATES
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	61/288,544		UNITED STATES
1H-PYRROLO[2,3-B]PYRIDINE AND THERAPEUTIC USES THEREOF	61/289,658		UNITED STATES
1H-PYRAZOLO[3,4-c]PYRIDINE AND THERAPEUTIC USES THEREOF	61/297,461		UNITED STATES
1H-PYRAZOLO[4,3-b]PYRIDINE AND THERAPEUTIC USES THEREOF	61/297,449		UNITED STATES
INDAZOLES AND THERAPEUTIC USES THEREOF	61/305,459		UNITED STATES
INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF	12/852,681	US-2011-0034441-A1	UNITED STATES
INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF	BR112012002942-8		BRAZIL

INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF	2770320		CANADA
INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF	201080044980.5	CN 102595899 A	CHINA
INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF	10808586.1	2464231	EUROPEAN PATENT CONVENTION
INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF	2053/CHENP/2012	2053/CHENP/2012 A	INDIA
INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF	UNKNOWN		INDIA
INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF	2012-524772	2013-501792	JAPAN
INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF	PCT/US2010/044865	WO2011/019648	WIPO
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	12/852,706	US 2011-0034497 A1	UNITED STATES
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		ALBANIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		AUSTRIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		BELGIUM
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	15177852.9		BELGIUM
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		BULGARIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	BR112012002854-5		BRAZIL
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	2770116		CANADA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		SWITZERLAND

INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	15177852.9		SWITZERLAND
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	201080044979.2	CN 102595900A	CHINA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	201510344619.9	CN105037355A	CHINA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		CYPRUS
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		CZECH REPUBLIC
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5	2464232	GERMANY
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	15177852.9		GERMANY
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		DENMARK
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	15177852.9		DENMARK
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		ESTONIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5	2464232	EUROPEAN PATENT CONVENTION
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	15177852.9	2987487	EUROPEAN PATENT CONVENTION
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		SPAIN
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	15177852.9		SPAIN
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		FINLAND
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		FRANCE

INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	15177852.9		FRANCE
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		UNITED KINGDOM
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	15177852.9		UNITED KINGDOM
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		GREECE
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	16110093.7	1224176	HONG KONG
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		CROATIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		HUNGARY
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		IRELAND
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	15177852.9		IRELAND
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	2086/CHENP/2012	2086/CHENP/2012 A	INDIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		ICELAND
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		ITALY
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	15177852.9		ITALY
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	2012-524773	2013-501793	JAPAN
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	2015-117679	2015-180681	JAPAN
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	2016-219613	2017-025113	JAPAN

INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		LITHUANIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		LUXEMBOURG
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		LATVIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		MONACO
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	15177852.9		MONACO
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		MACEDONIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		MALTA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	15177852.9		MALTA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		NETHERLANDS
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	15177852.9		NETHERLANDS
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		NORWAY
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		POLAND
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		PORTUGAL
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		ROMANIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		SWEDEN
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	15177852.9		SWEDEN

INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		SLOVENIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		SLOVAKIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		SAN MARINO
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10808589.5		TURKEY
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	15177852.9		TURKEY
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	PCT/US2010/044872	WO2011/019651	WIPO
β - and γ -diketones and γ -hydroxyketones as Wnt/ β -catenin signaling pathway activators	61/374,687		UNITED STATES
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	12/968,505	US-2011-0190290-A1	UNITED STATES
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		ALBANIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		AUSTRIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	10842538.0		BELGIUM
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		BELGIUM
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	17187452.2		BELGIUM
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		BULGARIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	BR112012018413-0		BRAZIL
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	2785037		CANADA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	2986631		CANADA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	10842538.0		SWITZERLAND
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		SWITZERLAND

1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	17187452.2		SWITZERLAND
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	201080061866.3	CN 102821607 A	CHINA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	201410724424.2	104546846A	CHINA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		CYPRUS
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		CZECH REPUBLIC
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	10842538.0		GERMANY
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		GERMANY
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	17187452.2	3305073	GERMANY
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		DENMARK
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		ESTONIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	10842538.0	2515655	EUROPEAN PATENT CONVENTION
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7	3001903	EUROPEAN PATENT CONVENTION
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	17187452.2	3305073	EUROPEAN PATENT CONVENTION
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	10842538.0		SPAIN
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		SPAIN
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		FINLAND
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	10842538.0		FRANCE
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		FRANCE
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	17187452.2		FRANCE
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	10842538.0		UNITED KINGDOM
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		UNITED KINGDOM

1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	17187452.2		UNITED KINGDOM
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		GREECE
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	16111598.5	1223247	HONG KONG
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	18112659.7	1253364	HONG KONG
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		CROATIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		HUNGARY
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	10842538.0		IRELAND
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		IRELAND
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	17187452.2		IRELAND
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	6429/CHENP/2012		INDIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	201848041368	201848041368A	INDIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		ICELAND
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	10842538.0		ITALY
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		ITALY
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	2012-546046		JAPAN
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	2015-198552	2016-047823	JAPAN
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	2017-099888	2017-137359	JAPAN
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		LITHUANIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		LUXEMBOURG
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		LATVIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	10842538.0		MONACO

1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		MONACO
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	17187452.2		MONACO
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7	3001903	MACEDONIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		MALTA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	10842538.0		NETHERLANDS
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		NETHERLANDS
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	17187452.2		NETHERLANDS
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		NORWAY
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		POLAND
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		PORTUGAL
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		ROMANIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		SERBIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	10842538.0		SWEDEN
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		SWEDEN
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		SLOVENIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		SLOVAKIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		SAN MARINO
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	10842538.0		TURKEY
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15174246.7		TURKEY
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	PCT/US2010/060514	WO2011/084486	WIPO
B- AND Y-DIKETONES AND Y-HYDROXYKETONES AS WNT/B-CATENIN SIGNALING PATHWAY ACTIVATORS	61/427,974		UNITED STATES

BETA- AND GAMMA-DIKETONES AND GAMMA-HYDROXYKETONES AS WNT/BETA-CATENIN SIGNALING PATHWAY ACTIVATORS	13/211,665	US-2012-0046320-A1	UNITED STATES
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		ALBANIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		ALBANIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		AUSTRIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		AUSTRIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	2011291989		AUSTRALIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	2015258299		AUSTRALIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	2018200333	20182000333	AUSTRALIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		BELGIUM
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		BELGIUM
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		BULGARIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		BULGARIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	BR112013003631-1	BR112013003631-1	BRAZIL
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	2807419		CANADA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		SWITZERLAND
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		SWITZERLAND
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	201180050153.1	CN 103153053 A	CHINA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	201510019522.0	CN 104672202	CHINA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		CYPRUS
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		CYPRUS
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		CZECH REPUBLIC

DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		CZECH REPUBLIC
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7	2605652	GERMANY
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9	3311666	GERMANY
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		DENMARK
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		DENMARK
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		ESTONIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		ESTONIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7	2605652	EUROPEAN PATENT CONVENTION
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9	3311666	EUROPEAN PATENT CONVENTION
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	21167222.5	3915367	EUROPEAN PATENT CONVENTION
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		SPAIN
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		SPAIN
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		FINLAND
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		FINLAND
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		FRANCE
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		FRANCE
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		UNITED KINGDOM
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		UNITED KINGDOM
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		GREECE
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		GREECE
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	13113745.6	1186347A	HONG KONG

DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	18113605.0	1254638	HONG KONG
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		CROATIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		CROATIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		HUNGARY
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		HUNGARY
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		IRELAND
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		IRELAND
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	1345/CHENP/2013	1345/CHENP/2013 A	INDIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		ICELAND
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		ICELAND
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7	2605652	ITALY
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9	3311666	ITALY
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	2013-524961	2013-535515	JAPAN
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	2016-181627	2017-048192	JAPAN
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	2017-116469	2017-165773	JAPAN
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		LITHUANIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		LITHUANIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		LUXEMBOURG
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		LUXEMBOURG
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		LATVIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		LATVIA

DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		MONACO
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		MONACO
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		MACEDONIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		MACEDONIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	J/002745		MACAO
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		MALTA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		MALTA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	MX/a/2013/001940		MEXICO
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	MX/a/2016/010036		MEXICO
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	MX/a/2018/001868		MEXICO
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		NETHERLANDS
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		NETHERLANDS
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		NORWAY
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		NORWAY
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		POLAND
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		POLAND
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		PORTUGAL
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		PORTUGAL
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		ROMANIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		ROMANIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		SERBIA

DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		SERBIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	2013111835		RUSSIAN FEDERATION
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	2016124136	2016124136A	RUSSIAN FEDERATION
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		SWEDEN
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		SWEDEN
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		SLOVENIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		SLOVENIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		SLOVAKIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		SLOVAKIA
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		SAN MARINO
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9		SAN MARINO
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	11818727.7		TURKEY
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	17193280.9	3311666	TURKEY
DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS	PCT/US2011/048086	WO2012/024404	WIPO
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	61/534,601		UNITED STATES
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	61/620,107		UNITED STATES
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	61/624,646		UNITED STATES
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	61/642,915		UNITED STATES
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13/552,188	US-2013-0040976-A1	UNITED STATES

INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	13/614,296	US-2013-0079329-A1	UNITED STATES
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	253/2014		UNITED ARAB EMIRATES
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		ALBANIA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		AUSTRIA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	2012308570		AUSTRALIA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	2017200866	2017200866	AUSTRALIA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		BOSNIA AND HERZEGOVINA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		BELGIUM
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		BULGARIA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	BR1120140061270		BRAZIL
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	BR1220200244690		BRAZIL
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	2848659		CANADA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		SWITZERLAND
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	00642-2014		CHILE
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	201280055729.8	CN 103929963A	CHINA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	201811620778.7	CN 109705097 A	CHINA

INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	14-080375		COLOMBIA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		CYPRUS
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		CZECH REPUBLIC
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		GERMANY
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		DENMARK
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		ESTONIA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	PCT 395/2014		EGYPT
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2	2755483	EUROPEAN PATENT CONVENTION
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	18191545.5	3473099	EUROPEAN PATENT CONVENTION
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		SPAIN
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		FINLAND
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		FRANCE
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		UNITED KINGDOM
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		GREECE
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	14107549.5	1193946A	HONG KONG
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	19129522.9	40006001	HONG KONG

INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		CROATIA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		HUNGARY
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	P00201402058	2015/02022	INDONESIA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		IRELAND
INDAZOLE-3-CARBOXAMIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF DISEASES	231536		ISRAEL
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY	2646/CHENP/2014	2646/CHENP/2014 A	INDIA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		ICELAND
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		ITALY
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	2014-530787	2014-526510	JAPAN
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	2016-202360	2017-036317	JAPAN
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	10-2014-7009764		SOUTH KOREA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	2014/1559.1		KAZAKHSTAN
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	2016/0164.1		KAZAKHSTAN
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		LITHUANIA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		LUXEMBOURG

INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		LATVIA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	36905		MOROCCO
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		MONACO
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		MONTENEGRO
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		MACEDONIA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		MALTA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	MX/a/2014/003225		MEXICO
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	MX/a/2016/010907		MEXICO
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	MX/a/2019/000845		MEXICO
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	PI 2014000732		MALAYSIA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	PI 2018001219		MALAYSIA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		NETHERLANDS
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		NORWAY
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	622483		NEW ZEALAND
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	000356-2014/DIN		PERU
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	1-2014-500594		PHILIPPINES

INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		POLAND
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		PORTUGAL
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		ROMANIA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2	2755483	SERBIA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	2014114466		RUSSIAN FEDERATION
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		SWEDEN
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	11201400666P		SINGAPORE
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	10201914121Y		SINGAPORE
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	10202002005S		SINGAPORE
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		SLOVENIA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		SLOVAKIA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		SAN MARINO
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	1401001414	1401001414A	THAILAND
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	12830938.2		TURKEY
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	PCT/US2012/055172	WO 2013/040215	WIPO
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	2014/02623		SOUTH AFRICA

INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	2015/02062		SOUTH AFRICA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	2016/00169		SOUTH AFRICA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	2017/04611		SOUTH AFRICA
3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	61/750,221		UNITED STATES
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	61/768,033		UNITED STATES
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13/800,963	US-2013-0267495-A1	UNITED STATES
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	1053/2014		UNITED ARAB EMIRATES
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		ALBANIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		AUSTRIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	2013243899		AUSTRALIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	2016203274		AUSTRALIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		BOSNIA AND HERZEGOVINA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		BELGIUM
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		BULGARIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	BR1120140236399		BRAZIL
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	2853703		CANADA

INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		SWITZERLAND
3-(IMIDAZO[4,5-C]PYRIDIN-2-YL)-INDAZOLE DERIVATIVE COMPOUNDS, INHIBITORS OF ONE OR MORE PROTEINS IN THE WNT SIGNAL PATHWAY; PHARMACEUTICAL COMPOSITION; AND METHOD FOR TREATING A DISORDER OR DISEASE IN WHICH ABERRANT WNT SIGNALING IS IMPLICATED, SUCH AS CANCER, OSTEOARTHRITIS AND ALZHEIMER'S DISEASE, INTER ALIA	02511-2014		CHILE
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	201380018954.9	CN 104202984 A	CHINA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	201710116940.0	CN 106892916 A	CHINA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	14-219345		COLOMBIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		CYPRUS
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		CZECH REPUBLIC
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9	2760285	GERMANY
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		DENMARK
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		ESTONIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	PCT 1578/2014		EGYPT
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9	2760285	EUROPEAN PATENT CONVENTION
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	17169783.2	3284744	EUROPEAN PATENT CONVENTION
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	21170540.5	3915988	EUROPEAN PATENT CONVENTION

INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		SPAIN
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		FINLAND
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		FRANCE
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		UNITED KINGDOM
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		GREECE
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	14108066.6	1194616A	HONG KONG
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		CROATIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		HUNGARY
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	P00201405884	2016/02031	INDONESIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	P00201901121		INDONESIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		IRELAND
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	234743		ISRAEL
2-(INDAZOL-3-YL)-IMIDAZO[4,5-c]PYRIDINE DERIVATIVES AS INHIBITORS OF THE WNT SIGNAL PATHWAY	254935		ISRAEL
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	7914/CHENP/2014	7914/CHENP/2014 A	INDIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	201948011142	201948011142 A	INDIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		ICELAND

INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9	2760285	ITALY
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	2015-504582	2015-512443	JAPAN
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	2017-124183	2017-214393	JAPAN
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	2018-166480	2018-188479	JAPAN
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10-2014-7028706		SOUTH KOREA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	2014/2521.1		KAZAKHSTAN
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		LITHUANIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		LUXEMBOURG
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		LATVIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	37450		MOROCCO
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		MONACO
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		MONTENEGRO
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		MACEDONIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	J/002653		MACAO
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		MALTA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	MX/a/2014/011996		MEXICO

INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	MX/a/2018/004730		MEXICO
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	PI 2014002843		MALAYSIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	PI 2018002659		MALAYSIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		NETHERLANDS
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		NORWAY
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	629323		NEW ZEALAND
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	727358		NEW ZEALAND
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	740938		NEW ZEALAND
(N-5-(3-(7-(3-FLUOROPHENYL)-3HIMIDAZOL[4,5-c]PYRIDIN-2-PY)-1H-INDAZOL-5-YL) PYRIDIN-3-YL)-3-METHYLBUTANAMIDE AS INHIBITOR OF WNT SIGNALPATHWAY	001518-2014/DIN	001518-2014	PERU
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	1-2014-502183		PHILIPPINES
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	1-2017-500997	1-2017-500997	PHILIPPINES
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	1-2017-501588	70	PHILIPPINES
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		POLAND
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		PORTUGAL
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		ROMANIA

INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9	2760285	SERBIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	2014144309		RUSSIAN FEDERATION
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	2017143402		RUSSIAN FEDERATION
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		SWEDEN
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	11201406310R		SINGAPORE
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	10201610539R		SINGAPORE
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		SLOVENIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		SLOVAKIA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		SAN MARINO
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	1401005855	166192	THAILAND
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13772420.9		TURKEY
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	PCT/US2013/031055	WO 2013/151708	WIPO
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	2014/06273		SOUTH AFRICA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	2019/06377		SOUTH AFRICA
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	2019/06378		SOUTH AFRICA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13/855,874	US-2013-0225576-A1	UNITED STATES

1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13/887,177	US-2013-0296302-A1	UNITED STATES
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	1198/2014		UNITED ARAB EMIRATES
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		ALBANIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		AUSTRIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	2013256141		AUSTRALIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	2016213874		AUSTRALIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		BELGIUM
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		BULGARIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	BR1120140242844	BR1120140242844	BRAZIL
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	2,854,229		CANADA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		SWITZERLAND
1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVE COMPOUNDS, AS INHIBITORS OF ONE OR MORE PROTEINS IN THE WNT PATHWAY; PHARMACEUTICAL COMPOSITION COMPRISING THEM; AND USE THEREOF IN THE TREATMENT OF CANCER, DIABETIC RETINOPATHY, PULMONARY FIBROSIS, RHEUMATOID ARTHRITIS, ALZHEIMER'S DISEASE, INTER ALIA	02983-2014		CHILE
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	201380023502.X	CN 104271133 A	CHINA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	201710813857.9	107417707	CHINA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	14-219348		COLOMBIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		CYPRUS
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		CZECH REPUBLIC
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		GERMANY
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		DENMARK

1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		ESTONIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	PCT 1761/2014		EGYPT
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8	2770994	EUROPEAN PATENT CONVENTION
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	19179748.9	3593800	EUROPEAN PATENT CONVENTION
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		SPAIN
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		FINLAND
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		FRANCE
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		UNITED KINGDOM
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		GREECE
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	14110200.9	1197724A	HONG KONG
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		CROATIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		HUNGARY
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	P00201406368	2016/03336	INDONESIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	P00201901832		INDONESIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		IRELAND
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	235018	235018	ISRAEL
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	257312		ISRAEL
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	8595/CHENP/2014	8595/CHENP/2014 A	INDIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	201948025627	201948025627 A	INDIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		ICELAND
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		ITALY

1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	2015-510483	2015-515989	JAPAN
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	2017-173614	2018-021065	JAPAN
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	2018-139863	2018-162323	JAPAN
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	10-2014-7027960		SOUTH KOREA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	2014/2522.1		KAZAKHSTAN
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		LITHUANIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		LUXEMBOURG
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		LATVIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	37577		MOROCCO
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		MONACO
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8	2770994	MONTENEGRO
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		MACEDONIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	J/002910		MACAO
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		MALTA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	MX/a/2014/012009		MEXICO
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	MX/a/2019/000770		MEXICO
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	PI 2014003099		MALAYSIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		NETHERLANDS
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		NORWAY
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	629282		NEW ZEALAND
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	724837		NEW ZEALAND

1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	741907		NEW ZEALAND
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	001935-2014/DIN		PERU
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	1-2014-502369		PHILIPPINES
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	1-2017-501661	1-2017-501661	PHILIPPINES
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	1-2018-501552	37	PHILIPPINES
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		POLAND
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		PORTUGAL
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		ROMANIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		SERBIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	2014148773		RUSSIAN FEDERATION
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		SWEDEN
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	11201407148X		SINGAPORE
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	10201710585U	10201710585U	SINGAPORE
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		SLOVENIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		SLOVAKIA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8		SAN MARINO
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	1401006251	156848	THAILAND
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13784942.8	2770994	TURKEY
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	PCT/US2013/039484	WO 2013/166396	WIPO
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	2014/06274		SOUTH AFRICA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	2019/06379		SOUTH AFRICA

1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	2019/06380		SOUTH AFRICA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	13/938,692	US-2013-0296307-A1	UNITED STATES
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	13/938,691	US-2013-0296341-A1	UNITED STATES
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	14/019,103	US-2014-0005206-A1	UNITED STATES
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/BETA-CATENIN SIGNALING PATHWAY INHIBITORS	14/019,229	US-2014-0045815-A1	UNITED STATES
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	14/019,147	US-2014-0005383-A1	UNITED STATES
B- AND γ -DIKETONES AND γ -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS	14/019,092	US-2014-0005228-A1	UNITED STATES
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	14/019,940	US-2014-0005170-A1	UNITED STATES
B - AND γ -DIKETONES AND γ -HYDROXYKETONES AS WNT/B -CATENIN SIGNALING PATHWAY ACTIVATORS	14/086,529	US-2014-0080902-A1	UNITED STATES
3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF	14/149,948	US-2014-0194441-A1	UNITED STATES
3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	14737972.1		BELGIUM
3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	2897400		CANADA
3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	14737972.1		SWITZERLAND
3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	201480013031.9	CN 105120862 A	CHINA
3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	14737972.1		GERMANY
3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	14737972.1	2943198	EUROPEAN PATENT CONVENTION

3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	14737972.1		FRANCE
3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	14737972.1		UNITED KINGDOM
3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	14737972.1		IRELAND
3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	2015-551853	2016-504387	JAPAN
3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	MX/a/2015/008860		MEXICO
3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	14737972.1		NETHERLANDS
3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	14737972.1		SWEDEN
3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	PCT/US2014/010607	WO 2014/110086	WIPO
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	14/178,749	US-2014-0179696-A1	UNITED STATES
GAMMA-DIKETONES AS WNT/BETA - CATENIN SIGNALING PATHWAY ACTIVATORS	14/187,063	US-2014-0243349-A1	UNITED STATES
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	1059/2015		UNITED ARAB EMIRATES
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4	2968249	ALBANIA
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		AUSTRIA
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	2014218720		AUSTRALIA
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	2018275021		AUSTRALIA
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4	2968249	BOSNIA AND HERZEGOVINA
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		BELGIUM
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		BULGARIA

Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	BR 11 2015 020391 4	JOURNAL # 2537	BRAZIL
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	2901671		CANADA
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		SWITZERLAND
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	02363-2015		CHILE
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	01367-2016		CHILE
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	01274-2019		CHILE
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	201480022762.X	CN105188696A	CHINA
GAMMA-DIKETONES AS WNT/ β -CATENIN SIGNALING PATHWAY ACTIVATORS	15-224754		COLOMBIA
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		CYPRUS
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4	2968249T3	CZECH REPUBLIC
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4	2968249	GERMANY
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		DENMARK
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		ESTONIA
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	PCT 1302/2015		EGYPT
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4	2968249	EUROPEAN PATENT CONVENTION
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	18182474.9	3456325	EUROPEAN PATENT CONVENTION
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		SPAIN
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		FINLAND
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		FRANCE
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		UNITED KINGDOM
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		GREECE

Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	16102931.0	1214953A	HONG KONG
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4	HR P20190142 T1	CROATIA
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		HUNGARY
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	P00201505264	2016/05522	INDONESIA
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		IRELAND
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	240628		ISRAEL
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	5692/CHENP/2015	5692/CHENP/2015 A.	INDIA
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		ICELAND
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		ITALY
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	2015-559015	2016-514100	JAPAN
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	2018-166538	2019-031496	JAPAN
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	10-2015-7026034		SOUTH KOREA
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	2015/1037.1		KAZAKHSTAN
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		LITHUANIA
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		LUXEMBOURG
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		LATVIA
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	38421		MOROCCO
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		MONACO
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		MONTENEGRO
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		MACEDONIA
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		MALTA

Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	MX/a/2015/010948		MEXICO
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	PI 2015002083		MALAYSIA
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	PI2020004302		MALAYSIA
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		NETHERLANDS
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		NORWAY
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	711126		NEW ZEALAND
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	750800		NEW ZEALAND
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	001796-2015/DIN		PERU
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	1-2015-501847		PHILIPPINES
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		POLAND
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		PORTUGAL
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		ROMANIA
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4	2968249	SERBIA
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	2015140118	2015140118A	RUSSIAN FEDERATION
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	2019104082	2019104082A	RUSSIAN FEDERATION
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		SWEDEN
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	11201506592S		SINGAPORE
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		SLOVENIA
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4	30145	SLOVAKIA
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		SAN MARINO
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	1501004770	1501004770A	THAILAND

Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	14753569.4		TURKEY
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	PCT/US2014/017794	WO 2014/130869	WIPO
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	2015/06438		SOUTH AFRICA
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	61/968,350		UNITED STATES
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	14/331,427	US-2014-0323479-A1	UNITED STATES
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	14/334,005	US-2015-0045379-A1	UNITED STATES
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	14/454,279	US-2015-0072981-A1	UNITED STATES
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	62/039,786		UNITED STATES
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	14/465,056	US-2015-0045360-A1	UNITED STATES
2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF	62/047,324		UNITED STATES
2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF	62/047,401		UNITED STATES
3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF	62/047,509		UNITED STATES
3-(3H-imidazo[4,5-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]Pyridine Compound	62/047,395		UNITED STATES
3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF	62/047,438		UNITED STATES
3-(3H-imidazo[4,5-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]Pyridine and therapeutic uses thereof	62/047,371		UNITED STATES
3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF	62/047,406		UNITED STATES
3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF	62/047,575		UNITED STATES
3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF	62/051,567		UNITED STATES

INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS	62/061,762		UNITED STATES
TREATMENT OF OSTEOARTHRITIS	62/080,052		UNITED STATES
B- AND γ -DIKETONES AND γ -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS	14/547,858	US-2015-0299174-A1	UNITED STATES
B- AND γ -DIKETONES AND γ -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS	14/547,951	US-2015-0299157-A1	UNITED STATES
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	14/621,195	US-2015-0152105-A1	UNITED STATES
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	14/621,222	US-2015-0150862-A1	UNITED STATES
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	14/664,517	US-2015-0266825-A1	UNITED STATES
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	1001/2016		UNITED ARAB EMIRATES
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	2015230999		AUSTRALIA
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	BR1120160216261		BRAZIL
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	2942687		CANADA
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	02364-2016		CHILE
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	201580026082.X	CN 106535890 A	CHINA
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	NC2016/0003114		COLOMBIA
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	1528/2016		EGYPT
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	15765201.7	3119393	EUROPEAN PATENT CONVENTION

5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	P00 2016 07079	2017/12902	INDONESIA
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	247713		ISRAEL
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	201647035091	201647035091 A	INDIA
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	2016-558073	2017-508763	JAPAN
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	10-2016-7028641		SOUTH KOREA
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	2016/0921.1		KAZAKHSTAN
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	MX/a/2016/012208		MEXICO
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	PI2016001696		MALAYSIA
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	724380		NEW ZEALAND
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	001658-2016/DIN	001658-2016/DIN	PERU
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	1-2016-501835		PHILIPPINES
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	2016141088		RUSSIAN FEDERATION
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	11201607816U		SINGAPORE
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	10201914111X		SINGAPORE
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	1601005463		THAILAND
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	PCT/US2015/021847	WO 2015/143380	WIPO

5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	2016/06455		SOUTH AFRICA
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	14/718,354	US-2016-0101092-A1	UNITED STATES
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	14/741,645	US-2016-0128991-A1	UNITED STATES
3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF	62/200,226		UNITED STATES
3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF	62/200,190		UNITED STATES
3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF	62/200,229		UNITED STATES
3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF	62/200,187		UNITED STATES
3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF	62/200,468		UNITED STATES
3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF	62/200,433		UNITED STATES
3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF	62/200,450		UNITED STATES
3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF	62/200,412		UNITED STATES
3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	62/200,426		UNITED STATES
3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	62/200,392		UNITED STATES
3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	62/200,279		UNITED STATES
3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	62/200,301		UNITED STATES
3-(1H-INDOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	62/200,195		UNITED STATES

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	62/200,201		UNITED STATES
3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	62/200,259		UNITED STATES
3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	62/200,275		UNITED STATES
3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	62/200,492		UNITED STATES
3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	62/200,377		UNITED STATES
3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	62/200,423		UNITED STATES
3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	62/200,329		UNITED STATES
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	14/831,456	US-2016-0206540-A1	UNITED STATES
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		ALBANIA
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		AUSTRIA
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	2015305373		AUSTRALIA
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		BOSNIA AND HERZEGOVINA
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		BELGIUM
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		BULGARIA
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	BR1120170039591		BRAZIL
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	2958580		CANADA

GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		SWITZERLAND
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	00410-2017		CHILE
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	201580056841.7	CN107106549A	CHINA
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		CYPRUS
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		CZECH REPUBLIC
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2	3206686	GERMANY
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		DENMARK
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		ESTONIA
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2	3206686	EUROPEAN PATENT CONVENTION
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		SPAIN
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		FINLAND
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		FRANCE
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		UNITED KINGDOM
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		GREECE
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	17113534.7	1240093	HONG KONG
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		CROATIA

GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		HUNGARY
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	PID201701633	2018/02575	INDONESIA
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		IRELAND
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	250663		ISRAEL
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		ICELAND
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		ITALY
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	2017-529598	2017-525767	JAPAN
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	10-2017-7007464		SOUTH KOREA
GAMMA-DIKETONES FOR IMPROVING THE AESTHETIC APPEARANCE OF SKIN	2017/0188.1		KAZAKHSTAN
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		LITHUANIA
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		LUXEMBOURG
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		LATVIA
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		MOROCCO
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		MONACO
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		MONTENEGRO
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		MACEDONIA

GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		MALTA
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	MX/a/2017/002285	MX/a/2017/002285	MEXICO
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		NETHERLANDS
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		NORWAY
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	729288		NEW ZEALAND
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	767230		NEW ZEALAND
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		POLAND
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		PORTUGAL
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		ROMANIA
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		SERBIA
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	2017108750	2017108750	RUSSIAN FEDERATION
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		SWEDEN
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		SLOVENIA
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		SLOVAKIA
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		SAN MARINO
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15833863.2		TURKEY

GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	PCT/US2015/046120	WO 2016/029021	WIPO
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	2017/01460		SOUTH AFRICA
2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF	PCT/US2015/048668	WO 2016/040182	WIPO
2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF	PCT/US2015/048683	WO 2016/040185	WIPO
3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF	PCT/US2015/048660	WO 2016/040180	WIPO
3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF	PCT/US2015/048663	WO 2016/040181	WIPO
3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF	PCT/US2015/048689	WO 2016/040188	WIPO
3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF	PCT/US2015/048680	WO 2016/040184	WIPO
3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF	PCT/US2015/048709	WO 2016/040193	WIPO
3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF	PCT/US2015/048705	WO 2016/040190	WIPO
2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF	14/847,259	US-2016-0075701-A1	UNITED STATES
2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF	14/847,336	US-2016-0090380-A1	UNITED STATES
3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF	14/847,299	US-2016-0068529-A1	UNITED STATES
3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF	14/847,287	US-2016-0068547-A1	UNITED STATES
3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF	14/847,344	US-2016-0068548-A1	UNITED STATES
3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF	14/847,394	US-2016-0068551-A1	UNITED STATES

3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF	14/847,371	US-2016-0068549-A1	UNITED STATES
3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF	14/847,379	US-2016-0068550-A1	UNITED STATES
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	62/245,014		UNITED STATES
TREATMENT OF OSTEOARTHRITIS	62/252,332		UNITED STATES
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	14/939,434	US-2016-0297812-A1	UNITED STATES
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/BETA-CATENIN SIGNALING PATHWAY INHIBITORS	14/940,958	US-2016-0304488-A1	UNITED STATES
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	14/962,681	US-2016-0318954-A1	UNITED STATES
TREATMENT REGIMENS AND COMPOSITIONS CONTAINING GAMMA-DIKETONES FOR MODULATING HAIR GROWTH	62/277,019		UNITED STATES
COMBINATION TREATMENT REGIMENS AND COMPOSITIONS CONTAINING GAMMA-DIKETONES FOR MODULATING HAIR GROWTH	62/277,021		UNITED STATES
COMBINATION TREATMENT REGIMENS AND COMPOSITIONS CONTAINING GAMMA-DIKETONES FOR MODULATING HAIR GROWTH	62/289,614		UNITED STATES
TREATMENT OF OSTEOARTHRITIS	62/303,168		UNITED STATES
3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B] PYRIDINES AND THERAPEUTIC USES THEREOF	62/313,506		UNITED STATES
3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	62/313,535		UNITED STATES
3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B] PYRIDINES AND THERAPEUTIC USES THEREOF	62/313,568		UNITED STATES
3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B] PYRIDINES AND THERAPEUTIC USES THEREOF	62/313,576		UNITED STATES
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	62/328,210		UNITED STATES

ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	62/328,255		UNITED STATES
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	62/344,170		UNITED STATES
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	15/184,553	US-2017-0065574-A1	UNITED STATES
3-(1H-INDOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	62/353,947		UNITED STATES
3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	62/354,000		UNITED STATES
3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	62/354,014		UNITED STATES
3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	62/354,021		UNITED STATES
3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	62/356,068		UNITED STATES
3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	62/356,103		UNITED STATES
3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	62/356,108		UNITED STATES
3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	62/356,133		UNITED STATES
Gamma-Diketones As WNT/ β -Catenin Signaling Pathway Activators	10201606032V		SINGAPORE
3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF	PCT/US2016/045269	WO 2017/023986	WIPO
3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF	PCT/US2016/045304	WO 2017/024010	WIPO
3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF	PCT/US2016/045309	WO 2017/024013	WIPO
3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF	PCT/US2016/045326	WO 2017/024021	WIPO

3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF	PCT/US2016/045333	WO 2017/024026	WIPO
3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF	PCT/US2016/045267	WO 2017/023984	WIPO
3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF	PCT/US2016/045256	WO 2017/023975	WIPO
3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF	PCT/US2016/045261	WO 2017/023980	WIPO
3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	PCT/US2016/045252	WO 2017/023973	WIPO
3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	PCT/US2016/045270	WO 2017/023987	WIPO
3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	PCT/US2016/045263	WO 2017/023981	WIPO
3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	PCT/US2016/045283	WO 2017/023996	WIPO
3-(1H-INDOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	PCT/US2016/045278	WO 2017/023993	WIPO
3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	PCT/US2016/045293	WO 2017/024003	WIPO
3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	PCT/US2016/045332	WO 2017/024025	WIPO
3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	PCT/US2016/045296	WO 2017/024004	WIPO
3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	PCT/US2016/045272	WO 2017/023989	WIPO
3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	PCT/US2016/045251	WO 2017/023972	WIPO
3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	PCT/US2016/045271	WO 2017/023988	WIPO
3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	PCT/US2016/045311	WO 2017/024015	WIPO

1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15/244,687	US-2017-0202846-A1	UNITED STATES
3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF	15/257,398	US-2017-0216299-A1	UNITED STATES
3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF	15/267,939	US-2017-0224697-A1	UNITED STATES
2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF	15/298,346	US-2017-0260179-A1	UNITED STATES
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	62/411,478		UNITED STATES
TREATMENT OF OSTEOARTHRITIS	2016348639		AUSTRALIA
TREATMENT OF OSTEOARTHRITIS	BR1120180092525		BRAZIL
TREATMENT OF OSTEOARTHRITIS	BR1220200243520		BRAZIL
USE OF N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE IN THE TREATMENT OF OSTEOARTHRITIS	3004506		CANADA
POLYMORPH FORMS 2 TO 11 OF N-(5-(3-(7-(3-FLUOROPHENYL)-2,3-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE; COMPOSITION COMPRISING THEM; PHARMACEUTICAL COMPOSITION COMPRISING THEM; AND USE THEREOF IN THE TREATMENT OF OSTEOARTHRITIS	01230-2018		CHILE
TREATMENT OF OSTEOARTHRITIS	201680078031.6	CN 108472290 A	CHINA
TREATMENT OF OSTEOARTHRITIS	16863183.6	3370721	EUROPEAN PATENT CONVENTION
TREATMENT OF OSTEOARTHRITIS	19120638.2	1260763A	HONG KONG
TREATMENT OF OSTEOARTHRITIS	PID201803344	2018/09955	INDONESIA
TREATMENT OF OSTEOARTHRITIS	259110		ISRAEL
TREATMENT OF OSTEOARTHRITIS	2018-522974	2018-537437	JAPAN
TREATMENT OF OSTEOARTHRITIS	2021-172952	2022-009400	JAPAN
TREATMENT OF OSTEOARTHRITIS	10-2018-7015302		SOUTH KOREA
TREATMENT OF OSTEOARTHRITIS	2018/0322.1		KAZAKHSTAN
TREATMENT OF OSTEOARTHRITIS	MX/a/2018/005696	MX/a/2018/005696	MEXICO

TREATMENT OF OSTEOARTHRITIS	742200		NEW ZEALAND
TREATMENT OF OSTEOARTHRITIS	781454		NEW ZEALAND
TREATMENT OF OSTEOARTHRITIS	1-2018-500981		PHILIPPINES
TREATMENT OF OSTEOARTHRITIS	2018120728		RUSSIAN FEDERATION
TREATMENT OF OSTEOARTHRITIS	2022116124		RUSSIAN FEDERATION
TREATMENT OF OSTEOARTHRITIS	PCT/US2016/060868	WO 2017/079765	WIPO
TREATMENT OF OSTEOARTHRITIS	2018/03009		SOUTH AFRICA
PROCESS FOR PREPARING N-(5-(3-(7-(3- FLUOROPHENYL)-3H-IMIDAZO[4,5- C]PYRIDIN-2-YL)-1H-INDAZOL-5- YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	62/418,657		UNITED STATES
2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5- C]PYRIDINES AND THEIR ANTI- INFLAMMATORY USES THEREOF	3004297		CANADA
2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5- C]PYRIDINES AND THEIR ANTI- INFLAMMATORY USES THEREOF	201680075175.6	108473491 A	CHINA
2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5- C]PYRIDINES AND THEIR ANTI- INFLAMMATORY USES THEREOF	16863178.6	3371187	EUROPEAN PATENT CONVENTION
2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5- C]PYRIDINES AND THEIR ANTI- INFLAMMATORY USES THEREOF	19120645.7	1260770A	HONG KONG
2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5- C]PYRIDINES AND THEIR ANTI- INFLAMMATORY USES THEREOF	2018-523022	2018-538258	JAPAN
2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5- C]PYRIDINES AND THEIR ANTI- INFLAMMATORY USES THEREOF	10-2018-7015778		SOUTH KOREA
2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5- C]PYRIDINES AND THEIR ANTI- INFLAMMATORY USES THEREOF	MX/a/2018/005694	MX/a/2018/005694A	MEXICO
2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5- C]PYRIDINES AND THEIR ANTI- INFLAMMATORY USES THEREOF	PCT/US2016/060856	WO 2017/079759	WIPO
SINGLE-DOSE, READY-TO-USE INJECTABLE FORMULATIONS	62/418,688		UNITED STATES
B- AND γ -DIKETONES AND γ - HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS	15/349,118	US-2017-0246154-A1	UNITED STATES
GAMMA-DIKETONES AS WNT/BETA - CATENIN SIGNALING PATHWAY ACTIVATORS	15/356,903	US-2017-0260176-A1	UNITED STATES

3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF	15/357,494	US-2017-0260209-A1	UNITED STATES
3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF	15/363,086	US-2017-0267697-A1	UNITED STATES
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15/420,398	US-2017-0333409-A1	UNITED STATES
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	20170101056	20170101056A	ARGENTINA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	20170101055	P170101055A	ARGENTINA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	15/498,990	US-2017-0313681-A1	UNITED STATES
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	P6001479/2018		UNITED ARAB EMIRATES
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	2017258187		AUSTRALIA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	BR1120180721905		BRAZIL
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	3022044		CANADA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	03050-2018	03050-2018A	CHILE
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	02067-2019		CHILE
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	201780037470.7	CN109311819A	CHINA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	NC2018/0012655	NC2018/0012655	COLOMBIA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790411.7	3448838	GERMANY
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	PCT 1678/2018		EGYPT
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790411.7	3448838	EUROPEAN PATENT CONVENTION
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	21181038.7	3943086	EUROPEAN PATENT CONVENTION
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790411.7		FRANCE
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790411.7		UNITED KINGDOM

ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	19128582.4	40005208	HONG KONG
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	PID201808704	2019/01420	INDONESIA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790411.7		IRELAND
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	262495		ISRAEL
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	201817043030	201817043030A	INDIA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	2018-556921	2019-515931	JAPAN
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	10-2018-7034080		SOUTH KOREA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	2018/0868.1		KAZAKHSTAN
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	43605		MOROCCO
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	MX/a/2018/013173	MX/a/2018/013173A	MEXICO
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	PI 2018001773		MALAYSIA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	747581		NEW ZEALAND
ISOQUINOLIN-3-IL-CARBOXAMIDES DERIVATIVES AS Wnt INHIBITORS	002175-2018/DIN	2019-0260	PERU
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	1-2018-502259		PHILIPPINES
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	2018141379		RUSSIAN FEDERATION
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	11201809310P		SINGAPORE
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	10201914127P		SINGAPORE
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	1801006576		THAILAND
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	1-2018-05236	63780	VIET NAM
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	PCT/US2017/029797	WO 2017/189823	WIPO
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	2018/07307		SOUTH AFRICA

ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	15/499,013	US-2017-0313682-A1	UNITED STATES
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	P6001480/2018		UNITED ARAB EMIRATES
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		ALBANIA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6	3448386	AUSTRIA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	2017258193		AUSTRALIA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		BOSNIA AND HERZEGOVINA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		BELGIUM
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		BULGARIA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	BR112018072169-7		BRAZIL
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	3022002		CANADA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		SWITZERLAND
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	03065-2018	03065-2018A	CHILE
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	01343-2019	01343-2019A	CHILE
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	201780037225.6	CN109310690A	CHINA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	NC2018/0012299	NC2018/0012299	COLOMBIA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		CYPRUS
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		CZECH REPUBLIC
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6	3448386	GERMANY
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		DENMARK
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		ESTONIA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	PCT 1679/2018		EGYPT

ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6	3448386	EUROPEAN PATENT CONVENTION
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	21159576.4	3892276	EUROPEAN PATENT CONVENTION
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		SPAIN
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		FINLAND
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		FRANCE
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		UNITED KINGDOM
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6	3448386	GREECE
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	19128583.2	40005209	HONG KONG
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		CROATIA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		HUNGARY
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	PID201808699	2019/02166	INDONESIA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		IRELAND
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	262470		ISRAEL
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	201817043240	201817043240 A	INDIA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		ICELAND
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		ITALY
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	2018-556902	2019-514938	JAPAN
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	10-2018-7034084		SOUTH KOREA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	2018/0869.1		KAZAKHSTAN
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		LIECHTENSTEIN
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		LITHUANIA

ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		LUXEMBOURG
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		LATVIA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	43619		MOROCCO
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		MONACO
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		MOLDOVA, REPUBLIC OF
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6	3448386	MONTENEGRO
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6	3448386	MACEDONIA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	J/005584		MACAO
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		MALTA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	MX/a/2018/013174	MX/a/2018/013174A	MEXICO
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	PI 2018001772		MALAYSIA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		NETHERLANDS
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		NORWAY
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	747584		NEW ZEALAND
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	002194-2018/DIN	2019-0326	PERU
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	1-2018-502258		PHILIPPINES
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		POLAND
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		PORTUGAL
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		ROMANIA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6	3448386	SERBIA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	2018141395		RUSSIAN FEDERATION

ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		SWEDEN
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	11201809301Y		SINGAPORE
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	10201914054S		SINGAPORE
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		SLOVENIA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6		SLOVAKIA
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6	3448386	SAN MARINO
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	1801006577		THAILAND
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17790416.6	3448386	TURKEY
ISOQUINOLIN-3-YL CARBOXAMIDES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME	1-2018-05235	62591	VIET NAM
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	PCT/US2017/029805	WO 2017/189829	WIPO
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	2018/07308		SOUTH AFRICA
3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF	15/591,566	US-2018-0086754-A1	UNITED STATES
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	15/611,150	US-2017-0349584-A1	UNITED STATES
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		ALBANIA
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		AUSTRIA
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	2017274350		AUSTRALIA
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		BOSNIA AND HERZEGOVINA

PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		BELGIUM
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		BULGARIA
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	BR112018074725-4	BR112018074725-4	BRAZIL
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	3,026,076		CANADA
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		SWITZERLAND
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	201803423		CHILE
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	202100611		CHILE
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	201780044159.5	CN 109476660 A	CHINA
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		CYPRUS
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		CZECH REPUBLIC
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4	3464285	GERMANY
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		DENMARK

PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		ESTONIA
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4	3464285	EUROPEAN PATENT CONVENTION
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		SPAIN
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		FINLAND
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		FRANCE
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		UNITED KINGDOM
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		GREECE
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	19127647.6	40004188	HONG KONG
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		CROATIA
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		HUNGARY
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	PID201811032	2019/01128	INDONESIA
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	P00202103833		INDONESIA

PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		IRELAND
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	263362		ISRAEL
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	201817049677	201817049677 A	INDIA
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		ICELAND
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4	3464285	ITALY
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	2018-562996	2019-522640	JAPAN
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	10-2018-7038209		SOUTH KOREA
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		LITHUANIA
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		LUXEMBOURG
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		LATVIA
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		MOROCCO
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		MONACO

PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		MOLDOVA, REPUBLIC OF
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		MONTENEGRO
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		MACEDONIA
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	J/007113		MACAO
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		MALTA
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	MX/a/2018/014871		MEXICO
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	PI2018002260		MALAYSIA
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		NETHERLANDS
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		NORWAY
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	749580		NEW ZEALAND
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		POLAND
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		PORTUGAL

PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		ROMANIA
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		SERBIA
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	2018146432		RUSSIAN FEDERATION
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		SWEDEN
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	11201810683V		SINGAPORE
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	10201912248R		SINGAPORE
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		SLOVENIA
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		SLOVAKIA
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		SAN MARINO
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	1801007453	1801007453A	THAILAND
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17729694.4		TURKEY
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	1-2018-06062	63230	VIET NAM

PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	PCT/US2017/035411	WO 2017/210407	WIPO
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	2019/00018		SOUTH AFRICA
5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	15/653,747	US-2018-0127377-A1	UNITED STATES
2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF	15/661,231	US-2018-0148444-A1	UNITED STATES
3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF	15/668,992	US-2018-0141963-A1	UNITED STATES
3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF	15/673,834	US-2018-0177787-A1	UNITED STATES
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	15/681,035	US-2018-0153873-A1	UNITED STATES
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	15/706,908	US-2018-0193244-A1	UNITED STATES
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/BETA-CATENIN SIGNALING PATHWAY INHIBITORS	15/709,057	US-2018-0237416-A1	UNITED STATES
2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF	15/716,803	US-2018-0215753-A1	UNITED STATES
3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF	15/716,894	US-2018-0201624-A1	UNITED STATES
6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	62/574,568		UNITED STATES
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	2017345699		AUSTRALIA
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	BR112019008061-9		BRAZIL
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	3,041,291		CANADA

METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	201901079		CHILE
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	201780077830.6	CN110709082A	CHINA
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	17793807.3	3528808	GERMANY
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	17793807.3	3528808	EUROPEAN PATENT CONVENTION
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	17793807.3		FRANCE
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	17793807.3		UNITED KINGDOM
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	62020003293.1	40013960	HONG KONG
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	PID201903800	2019/07698	INDONESIA
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	17793807.3		IRELAND
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	266145		ISRAEL
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	2019-521131	2019-535672	JAPAN
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	2023-002816	2023-052343	JAPAN
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	10-2019-7014643		SOUTH KOREA
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	2019/0371.1		KAZAKHSTAN
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	MX/a/2019/004616		MEXICO
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	752835		NEW ZEALAND

METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	793551		NEW ZEALAND
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	2019114954		RUSSIAN FEDERATION
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	PCT/US2017/057536	WO 2018/075858	WIPO
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	2019/02869		SOUTH AFRICA
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	15/790,544	US-2018-0185343-A1	UNITED STATES
6-(6-MEMBERED HETEROARYL & ARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	62/577,818		UNITED STATES
6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL-(5-MEMBERED HETEROARYL) CARBOXAMIDES AND PREPARATION AND USE THEREOF	62/578,370		UNITED STATES
6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	62/578,691		UNITED STATES
DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	62/579,883		UNITED STATES
TREATMENT OF OSTEOARTHRITIS AND DOSING REGIMEN FOR N-(5-(3-(7-(3-FLUOROPHENYL)-3HIMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	62/581,639		UNITED STATES
TREATMENT OF OSTEOARTHRITIS AND DOSING REGIMEN FOR N-(5-(3-(7-(3-FLUOROPHENYL)-3HIMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	62/581,648		UNITED STATES
TREATMENT OF OSTEOARTHRITIS AND DOSING REGIMEN FOR N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	62/581,653		UNITED STATES
TREATMENT OF OSTEOARTHRITIS AND DOSING REGIMEN FOR N-(5-(3-(7-(3-FLUOROPHENYL)-3HIMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	62/581,655		UNITED STATES

SINGLE-DOSE, READY-TO-USE INJECTABLE FORMULATIONS	15/806,321	US-2018-0133199-A1	UNITED STATES
SINGLE-DOSE, READY-TO-USE INJECTABLE FORMULATIONS	17801245.6	3534878	EUROPEAN PATENT CONVENTION
SINGLE-DOSE, READY-TO-USE INJECTABLE FORMULATIONS	62020003972.0	40014126	HONG KONG
SINGLE-DOSE, READY-TO-USE INJECTABLE FORMULATIONS	2019-523778	2019-533702	JAPAN
SINGLE-DOSE, READY-TO-USE INJECTABLE FORMULATIONS	2022-171095	2023-011723	JAPAN
SINGLE-DOSE, READY-TO-USE INJECTABLE FORMULATIONS	10-2019-7015685		SOUTH KOREA
Single-dose, ready-to-use injectable formulations and processes for preparing such formulations	1-2019-03041	67789	VIET NAM
SINGLE-DOSE, READY-TO-USE INJECTABLE FORMULATIONS	PCT/US2017/060481	WO 2018/085865	WIPO
3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF	15/808,602	US-2018-0250269-A1	UNITED STATES
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15/812,629	US-2018-0256588-A1	UNITED STATES
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	15/833,917	US-2018-0093970-A1	UNITED STATES
3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF	15/843,818	US-2018-0325910-A1	UNITED STATES
B- AND γ -DIKETONES AND γ -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS	15/855,463	US-2018-0333400-A1	UNITED STATES
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	15/884,112	US-2018-0155323-A1	UNITED STATES
3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF	15/749,587	US-2018-0222891-A1	UNITED STATES
3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF	15/749,586	US-2018-0221350-A1	UNITED STATES
3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF	15/749,592	US-2018-0228780-A1	UNITED STATES
3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF	15/749,606	US-2018-0207141-A1	UNITED STATES
3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF	15/749,608	US-2018-0228781-A1	UNITED STATES

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF	15/749,701	US-2018-0214427-A1	UNITED STATES
3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF	15/749,706	US-2018-0221351-A1	UNITED STATES
3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF	15/749,713	US-2018-0228782-A1	UNITED STATES
3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15/749,718	US-2018-0214428-A1	UNITED STATES
3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15/749,721	US-2018-0221341-A1	UNITED STATES
3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15/749,741	US-2018-0221352-A1	UNITED STATES
3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15/749,727	US-2018-0228783-A1	UNITED STATES
3-(1H-INDOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15/749,739	US-2018-0228784-A1	UNITED STATES
3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15/749,737	US-2018-0214429-A1	UNITED STATES
3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15/749,742	US-2018-0370989-A1	UNITED STATES
3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15/749,868	US-2018-0228785-A1	UNITED STATES
3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15/749,929	US-2018-0230142-A1	UNITED STATES
3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15/749,910	US-2018-0221353-A1	UNITED STATES
3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15/749,923	US-2018-0221354-A1	UNITED STATES
3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF	15/749,922	US-2018-0222923-A1	UNITED STATES
3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING	15/889,403	US-2018-0162840-A1	UNITED STATES

PATHWAY AND THERAPEUTIC USES THEREOF			
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	62/634,656		UNITED STATES
GAMMA-DIKETONES AS WNT/BETA - CATENIN SIGNALING PATHWAY ACTIVATORS	15/918,086	US-2019-0055227-A1	UNITED STATES
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	15/925,157	US-2018-0208580-A1	UNITED STATES
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	15/943,864	US-2018-0222887-A1	UNITED STATES
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	15/968,555	US-2019-0071440-A1	UNITED STATES
TREATMENT OF OSTEOARTHRITIS	15/773,951	US-2019-0112304-A1	UNITED STATES
2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-C]PYRIDINES AND THEIR ANTI-INFLAMMATORY USES THEREOF	15/773,737	US-2018-0318292-A1	UNITED STATES
INDAZOLE CONTAINING MACROCYCLES AND THERAPEUTIC USES THEREOF	62/685,764		UNITED STATES
2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF	16/015,996	US-2019-0055238-A1	UNITED STATES
METHODS OF TREATING CANCER USING A CLK INHIBITOR	62/690,146		UNITED STATES
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	16/032,905	US-2019-0134013-A1	UNITED STATES
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	16/115,222	US-2019-0194187-A1	UNITED STATES
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	16/130,842	US-2019-0233396-A1	UNITED STATES
3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF	16/162,155	US-2019-0119303-A1	UNITED STATES
6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	16/164,447	US-2019-0119263-A1	UNITED STATES
6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	PCT/US2018/056560	WO 2019/079626	WIPO

6-(6-MEMBERED HETEROARYL & ARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	16/172,553	US-2019-0125740-A1	UNITED STATES
6-(6-MEMBERED HETEROARYL & ARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	PCT/US2018/057854	WO 2019/084497	WIPO
6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL-(5-MEMBERED HETEROARYL) CARBOXAMIDES AND PREPARATION AND USE THEREOF	16/172,589	US-2019-0125741-A1	UNITED STATES
6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL-(5-MEMBERED HETEROARYL) CARBOXAMIDES AND PREPARATION AND USE THEREOF	PCT/US2018/057853	WO 2019/084496	WIPO
DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	16/177,149	US-2019-0127370-A1	UNITED STATES
DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	PCT/US2018/058564	WO 2019/089835	WIPO
3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF	16/224,160	US-2019-0119276-A1	UNITED STATES
PYRAZOLE DERIVATIVES AS MODULATORS OF THE WNT/B-CATENIN SIGNALING PATHWAY	62/793,428		UNITED STATES
METHODS OF TREATING CARTILAGE DISORDERS THROUGH INHIBITION OF CLK AND DYRK	62/793,855		UNITED STATES
3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF	16/252,055	US-2019-0352279-A1	UNITED STATES
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	16/283,366	US-2019-0263821-A1	UNITED STATES
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	P6001200/20		UNITED ARAB EMIRATES
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	2019224075		AUSTRALIA
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	BR1120200170879		BRAZIL
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	3091913		CANADA

5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	02177-2020		CHILE
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	201980027314.1	CN 112020501 A	CHINA
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	NC2020/0011134		COLOMBIA
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	19711736.9	3755696	GERMANY
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	202092002		EURASIA
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	19711736.9	3755696	EUROPEAN PATENT CONVENTION
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	19711736.9		SPAIN
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	19711736.9		FRANCE
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	19711736.9		UNITED KINGDOM
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	62021026519.0	40038017	HONG KONG
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	P00202006282	2021/PID/03524	INDONESIA
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	276814		ISRAEL
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	202017039184		INDIA
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	19711736.9	3755696	ITALY
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	2020-544501	2021-516674	JAPAN
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	10-2020-7027174		SOUTH KOREA

5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	MX/a/2020/008852		MEXICO
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	PI2020004299		MALAYSIA
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	767282		NEW ZEALAND
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	001271-2020		PERU
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	1-2020-551300		PHILIPPINES
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	11202008029U		SINGAPORE
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	PCT/US2019/019129	WO 2019/165192	WIPO
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	2020/05196		SOUTH AFRICA
PYRAZOLE DERIVATIVES AS MODULATORS OF THE WNT/BETA-CATENIN SIGNALING PATHWAY	62/831,478		UNITED STATES
METHODS OF TREATING CANCER USING A CLK INHIBITOR	62/846,335		UNITED STATES
1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF	16/425,700	US-2020-0155525-A1	UNITED STATES
B- AND γ -DIKETONES AND γ -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS	16/430,741	US-2020-0121663-A1	UNITED STATES
INDAZOLE CONTAINING MACROCYCLES AND THERAPEUTIC USES THEREOF	16/440,284	US-2019-0382402-A1	UNITED STATES
INDAZOLE CONTAINING MACROCYCLES AND THERAPEUTIC USES THEREOF	PCT/US2019/037024	WO 2019/241540	WIPO
METHODS OF TREATING CANCER USING A CLK INHIBITOR	19824758.7	3813826	EUROPEAN PATENT CONVENTION
METHODS OF TREATING CANCER USING A CLK INHIBITOR	62021040860.0	40052437	HONG KONG
METHODS OF TREATING CANCER USING A CLK INHIBITOR	PCT/US2019/039301	WO 2020/006115	WIPO

INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	16/518,337	US-2020-0190082-A1	UNITED STATES
6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL-(5-MEMBERED HETEROARYL) CARBOXAMIDES AND PREPARATION AND USE THEREOF	16/528,023	US-2020-0155540-A1	UNITED STATES
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	16/534,455	US-2020-0222295-A1	UNITED STATES
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	16/576,308	US-2020-0239436-A1	UNITED STATES
GAMMA-DIKETONES AS WNT/BETA - CATENIN SIGNALING PATHWAY ACTIVATORS	16/577,592	US-2020-0223834-A1	UNITED STATES
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	16/703,321	US-2020-0299263-A1	UNITED STATES
TREATMENT OF OSTEOARTHRITIS	16/710,099	US-2020-0325133-A1	UNITED STATES
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	16/727,053	US-2020-0339536-A1	UNITED STATES
6-(6-MEMBERED HETEROARYL & ARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	16/738,391		UNITED STATES
PYRAZOLE DERIVATIVES AS MODULATORS OF THE WNT/B-CATENIN SIGNALING PATHWAY	PCT/US2020/013983	WO 2020/150545	WIPO
METHODS OF TREATING CARTILAGE DISORDERS THROUGH INHIBITION OF CLK AND DYRK	20704766.3	3911317	EUROPEAN PATENT CONVENTION
METHODS OF TREATING CARTILAGE DISORDERS THROUGH INHIBITION OF CLK AND DYRK	PCT/US2020/013995	WO 2020/150552	WIPO
ISOTOPIC ANALOGS OF 1-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1HPYRAZOLO[3,4-B]PYRIDIN-5-YL)PYRIDIN-3-YL)-N,N-DIMETHYLMETHANAMINE	62/969,968		UNITED STATES
6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	16/795,734		UNITED STATES
SOLID FORMS OF 1-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDIN-5-YL)PYRIDIN-3-YL)-N,N-DIMETHYLMETHANAMINE	62/979,462		UNITED STATES

PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	16/813,021	US-2021-0002273-A1	UNITED STATES
METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	16/915,316	US-2021-0121448-A1	UNITED STATES
SINGLE-DOSE, READY-TO-USE INJECTABLE FORMULATIONS	16/939,713	US-2021-0145807-A1	UNITED STATES
TREATMENT OF OSTEOARTHRITIS	17/108,544	US-2021-0292318-A1	UNITED STATES
2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-C]-PYRIDINES AND THEIR ANTI-INFLAMMATORY USES THEREOF	17/112,282	US-2021-0292319-A1	UNITED STATES
β - AND γ -DIKETONES AND γ -HYDROXYKETONES AS WNT/ β -CATENIN SIGNALING PATHWAY ACTIVATORS	17/113,895	US-2021-0353604-A1	UNITED STATES
METHODS OF TREATING CANCER USING A CLK INHIBITOR	17/254,352	US-2022-0062240-A1	UNITED STATES
5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF	17/138,098	US-2022-0402921-A1	UNITED STATES
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17/155,577	US-2022-0332698-A1	UNITED STATES
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	17/168,747	US-2023-0013144-A1	UNITED STATES
SOLID FORMS OF 1-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDIN-5-YL)PYRIDIN-3-YL)-N,N-DIMETHYLMETHANAMINE	PCT/US2021/018896	WO 2021/168341	WIPO
PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE	17/205,558	US-2022-0024914-A1	UNITED STATES
GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS	17/241,662	US-2023-0053726-A1	UNITED STATES
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS	17/346,808	US-2023-0047396-A1	UNITED STATES
GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES	17/362,177	US-2022-0087917-A1	UNITED STATES
METHODS OF TREATING CARTILAGE DISORDERS THROUGH INHIBITION OF CLK AND DYRK	17/423,761	US-2023-0000842-A1	UNITED STATES

ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17/495,281	US-2023-0104155-A1	UNITED STATES
1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF	63/254,713		UNITED STATES
7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF	63/254,708		UNITED STATES
PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF	63/254,733		UNITED STATES
7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF	63/330,480		UNITED STATES
PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF	63/347,757		UNITED STATES
4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF	63/355,076		UNITED STATES
SINGLE-DOSE, READY-TO-USE INJECTABLE FORMULATIONS	17/873,818	US-2023-0139639-A1	UNITED STATES
METHODS OF TREATING CANCER USING A DUAL PAN CLK/PAN DYRK INHIBITOR	63/405,179		UNITED STATES
PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF	671/2022		PAKISTAN
1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF	17/964,423	US-2023-0192686-A1	UNITED STATES
1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS	UNKNOWN		EUROPEAN PATENT CONVENTION
1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS	PCT/US2022/046395	WO 2023/064349	WIPO
7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF	17/964,470	US-2023-0167133-A1	UNITED STATES
7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF	P220102785	AR127357 A1	ARGENTINA
7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS	2022367221		AUSTRALIA
7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF	Unknown		CANADA
7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS	UNKNOWN		EUROPEAN PATENT CONVENTION
7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF	673/2022		PAKISTAN
7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF	2022-2289206	PY2022-2289206A	PARAGUAY
7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF	111138696	202330533	TAIWAN

7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF	39.978		URUGUAY
7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS	PCT/US2022/046409	WO 2023/064361	WIPO
PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF	17/964,489	US-2023-0312605-A1	UNITED STATES
PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF	P220102781	AR127353	ARGENTINA
PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A	2022367222		AUSTRALIA
PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A	BR112024007117-0		BRAZIL
PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A	Unknown		CANADA
PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A	UNKNOWN		CHINA
PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A	UNKNOWN		EUROPEAN PATENT CONVENTION
PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A	P00202403218		INDONESIA
PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A	UNKNOWN		ISRAEL
PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A	Unknown		INDIA
PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A	Unknown		JAPAN
PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A	UNKNOWN		SOUTH KOREA
PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A	UNKNOWN		MEXICO
PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF	2289204		PARAGUAY
PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A	11202402343T		SINGAPORE
PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF	111138697	202322800	TAIWAN
PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF	39.979		URUGUAY
PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A	PCT/US2022/046416	WO 2023/064366	WIPO
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF	17/990,133	US-2023-0286945-A1	UNITED STATES

4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF	63/427,322		UNITED STATES
METHODS OF TREATING CANCER USING A DUAL PAN CLK/PAN DYRK INHIBITOR	63/484,587		UNITED STATES
7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF	63/494,921		UNITED STATES
PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF	63/494,951		UNITED STATES
4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF	63/458,808		UNITED STATES
INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF	18/315,047	US-2024-0116927-A1	UNITED STATES
4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF	18/340,543	US-2024-0002391-A1	UNITED STATES
4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF	P230101623		ARGENTINA
4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF	420/2023		PAKISTAN
4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF	PCT/US2023/026100	WO 2023/250156	WIPO
4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF	112123677	202413379	TAIWAN
SINGLE-DOSE, READY-TO-USE INJECTABLE FORMULATIONS	18/487,565		UNITED STATES
4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF	63/614,120		UNITED STATES
PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF	PCT/US2024/023387		WIPO

SCHEDULES



SCHEDULE 2











TRADEMARK AND TRADEMARK APPLICATIONS

Mark	Country	Appl No	RegNo
BEYMOTI	AUSTRALIA	IR1530342	IR1530342
BEYMOTI	CANADA	IR1530342	IR1530342
BEYMOTI	CHINA	IR1530342	IR1530342
BEYMOTI	EUROPEAN UNION	IR1530342	IR1530342
BEYMOTI	JAPAN	IR1530342	IR1530342
BEYMOTI	NEW ZEALAND	IR1530342	IR1530342
BEYMOTI	SOUTH KOREA	IR1530342	IR1530342
BEYMOTI	UNITED KINGDOM	IR1530342	IR1530342
BEYMOTI	UNITED KINGDOM	UK00801530342	UK00801530342
BEYMOTI	UNITED STATES	88/864,499	
BEYMOTI	UNITED STATES	98/244,546	
BEYMOTI	WIPO	IR1530342	IR1530342
BIOSPLICE	AUSTRALIA	IR1648005	IR1648005
BIOSPLICE	CHINA	IR1648005	
BIOSPLICE	EUROPEAN UNION	IR1648005	
BIOSPLICE	FRANCE	234968733	234968733
BIOSPLICE	IRELAND		
BIOSPLICE	ITALY	302023000127236	
BIOSPLICE	JAPAN	IR1648005	IR1648005
BIOSPLICE	SOUTH KOREA	IR1648005	IR1648005
BIOSPLICE	SPAIN	4221155	
BIOSPLICE	TURKEY	IR1648005	IR1648005
BIOSPLICE	UNITED KINGDOM	IR1648005	IR1648005

BIOSPLICE	UNITED STATES	90/852,797	
BIOSPLICE	WIPO	IR1648005	IR1648005
BIOSPLICE (Logo) biosplice	AUSTRALIA	IR1651986	IR1651986
BIOSPLICE (Logo) biosplice	CHINA	IR1651986	
BIOSPLICE (Logo) biosplice	EUROPEAN UNION	IR1651986	IR1651986
BIOSPLICE (Logo) biosplice	JAPAN	IR1651986	IR1651986
BIOSPLICE (Logo) biosplice	SOUTH KOREA	IR1651986	IR1651986
BIOSPLICE (Logo) biosplice	TURKEY	IR1651986	IR1651986
BIOSPLICE (Logo) biosplice	UNITED KINGDOM	IR1651986	IR1651986
BIOSPLICE (Logo) biosplice	UNITED STATES	90/852,803	
BIOSPLICE (Logo) biosplice	WIPO	IR1651986	IR1651986
HEXIDITONE	EUROPEAN UNION	14998223	14998223
HEXIDITONE	TURKEY	201602460	201602460
HEXIDITONE	UNITED KINGDOM	UK00914998223	UK00914998223
HEXIDITONE	UNITED STATES	86/880,059	5,157,596
LXR-60	EUROPEAN UNION	14998256	14998256
LXR-60	TURKEY	201602465	201602465
LXR-60	UNITED KINGDOM	UK00914998256	UK00914998256
NEOZUME	AUSTRALIA	IR1531062	IR1531062
NEOZUME	CANADA	IR1531062	IR1531062
NEOZUME	CHINA	IR1531062	IR1531062
NEOZUME	EUROPEAN UNION	IR1531062	IR1531062
NEOZUME	JAPAN	IR1531062	IR1531062

NEOZUME	NEW ZEALAND	IR1531062	IR1531062
NEOZUME	SOUTH KOREA	IR1531062	IR1531062
NEOZUME	UNITED KINGDOM	IR1531062	IR1531062
NEOZUME	UNITED KINGDOM	UK00801531062	UK00801531062
NEOZUME	UNITED STATES	88/864,497	
NEOZUME	UNITED STATES	98/244,550	
NEOZUME	WIPO	IR1531062	IR1531062
REZMOBA	AUSTRALIA	IR1530348	IR1530348
REZMOBA	CANADA	IR1530348	IR1530348
REZMOBA	CHINA	IR1530348	IR1530348
REZMOBA	EUROPEAN UNION	IR1530348	IR1530348
REZMOBA	JAPAN	IR1530348	IR1530348
REZMOBA	NEW ZEALAND	IR1530348	IR1530348
REZMOBA	SOUTH KOREA	IR1530348	IR1530348
REZMOBA	UNITED KINGDOM	IR1530348	IR1530348
REZMOBA	UNITED KINGDOM	UK00801530348	UK00801530348
REZMOBA	UNITED STATES	88/864,495	
REZMOBA	UNITED STATES	98/244,555	
REZMOBA	WIPO	IR1530348	IR1530348
SAMUMED	AUSTRALIA	IR1164773	IR1164773
SAMUMED	BRAZIL	840541767	840541767
SAMUMED	CANADA	1630176	TMA1028195
SAMUMED	CHINA	IR1164773	IR1164773
SAMUMED	EUROPEAN UNION	IR1164773	IR1164773

SAMUMED	EUROPEAN UNION	017236449	017236449
SAMUMED	INDIA	2549091	
SAMUMED	JAPAN	IR1164773	IR1164773
SAMUMED	MEXICO	IR1164773	IR1164773
SAMUMED	RUSSIAN FEDERATION	IR1164773	
SAMUMED	SWITZERLAND	IR1164773	IR1164773
SAMUMED	TURKEY	201559575	201559575
SAMUMED	UNITED KINGDOM	UK00801164773	UK00801164773
SAMUMED	UNITED KINGDOM	UK00917236449	UK00917236449
SAMUMED	UNITED STATES	85/744,828	4,978,303
SAMUMED	UNITED STATES	85/981,832	4,573,534
SAMUMED	UNITED STATES	97/717,953	
SAMUMED	WIPO	IR1164773	IR1164773
SAMUMED & Design (Logo) 	INDIA	2477899	
SAMUMED (Chinese Characters) 赛慕MED	CHINA	17949949	17949949
SAMUMED (Stylized) samumed	RUSSIAN FEDERATION	2015729128	
SAMUMED and Design (logo) 	AUSTRALIA	IR1153987	IR1153987

SAMUMED and Design (logo) 	BRAZIL	840415206	
SAMUMED and Design (logo) 	CANADA	1612915	
SAMUMED and Design (logo) 	CHINA	IR1153987	
SAMUMED and Design (logo) 	EUROPEAN UNION	IR1153987	IR1153987
SAMUMED and Design (logo) 	JAPAN	IR1153987	
SAMUMED and Design (logo) 	MEXICO	1345848	1362740
SAMUMED and Design (logo) 	RUSSIAN FEDERATION	IR1153987	
SAMUMED and Design (logo) 	SWITZERLAND	568782013	648756
SAMUMED and Design (logo) 	UNITED STATES	85/744,843	
SAMUMED and Design (logo) 	WIPO		IR1153987

SCHEDULE 3

COPYRIGHT REGISTRATIONS/APPLICATIONS

N/A